Biologics in IgE-mediated food allergy: where are we know?

Biologics offer a meaningful advance in food allergy treatment by targeting key immune pathways with an agnostic approach, therefore, independent on the specific antigen-specificity. This may offer the benefit of targeting multiple food allergies and also, eventually, further co-morbidities. There is broad evidence for an excellent safety profile for omalizumab. Studies are ongoing on other biologicals to explore the efficacy alongside the safety. A new era is also opened by the introduction of biosimilar on the market, by dramatically amortizing the economic burden. With the availability of multiple therapeutic options, the challenge for clinicians is to provide a personalized approach, shaped on the specific patient's need.